Peptide Developability: How Should Immunogenicity and Safety Be Evaluated?
Adequate activity and pharmacokinetics do not settle immunogenicity risk. Connect molecular and product-quality evidence, fit-for-purpose ADA assays, and longitudinal clinical outcomes.





